Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

NCT00590343 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Neuroendocrine Tumors

Interventions

DRUG: vatalanib

Sponsor

Louisiana State University Health Sciences Center in New Orleans

Collaborators

[object Object]